APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Polypeptide Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Polypeptide Drug Market Outlook and Growth Opportunities 2026

Report ID 174027180420 December 2025193 pages

Choose your research edition.

Industry ResearchPolypeptide Drug Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Polypeptide Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Polypeptide Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Polypeptide Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Polypeptide Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Polypeptide Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Polypeptide Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Polypeptide Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Polypeptide Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Polypeptide Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Polypeptide Drug market include Takeda, Sanofi, Novartis, Roche, Lilly, Ferring Pharmaceuticals, AstraZeneca, SciClone Pharmaceuticals and Merck Serono, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Polypeptide Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Polypeptide Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Polypeptide Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Polypeptide Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Polypeptide Drug Segment by Company

Takeda

Sanofi

Novartis

Roche

Lilly

Ferring Pharmaceuticals

AstraZeneca

SciClone Pharmaceuticals

Merck Serono

Ipsen PHarma Biotech

Asahi Kasei

Polypeptide Drug Segment by Type

Injection

Oral Administration

Transdermal Administration

Lung Administration

Nasal Administration

Polypeptide Drug Segment by Application

Tumor Drug

Digestive System Drugs (Gastrointestinal Type)

Immunity Regulating Medicine (Allergy Infection and Immune)

Urinary System Drug

Bone and Connective Tissue Types (Thyroid hormones Drug)

Gynecologic or Obstetric Drug

Metabolic Drug (Insulin and Other Hypoglycemic Agents)

Polypeptide Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Polypeptide Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Polypeptide Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Polypeptide Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Polypeptide Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Polypeptide Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Polypeptide Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Polypeptide Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Polypeptide Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Polypeptide Drug industry.

Chapter 3: Detailed analysis of Polypeptide Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Polypeptide Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Polypeptide Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Polypeptide Drug Industry Trends Table 2. Polypeptide Drug Industry Drivers Table 3. Polypeptide Drug Industry Opportunities and Challenges Table 4. Polypeptide Drug Industry Restraints Table 5. Global Polypeptide Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Polypeptide Drug Revenue Share by Company (2021-2026) Table 7. Global Polypeptide Drug Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Polypeptide Drug Sales Volume Share by Company (2021-2026) Table 9. Global Polypeptide Drug Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Polypeptide Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Polypeptide Drug Key Company Manufacturing Base & Headquarters Table 12. Global Polypeptide Drug Company, Product Type & Application Table 13. Global Polypeptide Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Polypeptide Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Injection Table 18. Significant Companies of Oral Administration Table 19. Significant Companies of Transdermal Administration Table 20. Significant Companies of Lung Administration Table 21. Significant Companies of Nasal Administration Table 22. Global Polypeptide Drug Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 23. Global Polypeptide Drug Sales Volume by Type (2021-2026) & (Tons) Table 24. Global Polypeptide Drug Sales Volume by Type (2027-2032) & (Tons) Table 25. Global Polypeptide Drug Sales Volume Share by Type (2021-2026) Table 26. Global Polypeptide Drug Sales Volume Share by Type (2027-2032) Table 27. Global Polypeptide Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Polypeptide Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Polypeptide Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Polypeptide Drug Sales Value Share by Type (2021-2026) Table 31. Global Polypeptide Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Tumor Drug Table 33. Significant Companies of Digestive System Drugs (Gastrointestinal Type) Table 34. Significant Companies of Immunity Regulating Medicine (Allergy Infection and Immune) Table 35. Significant Companies of Urinary System Drug Table 36. Significant Companies of Bone and Connective Tissue Types (Thyroid hormones Drug) Table 37. Significant Companies of Gynecologic or Obstetric Drug Table 38. Significant Companies of Metabolic Drug (Insulin and Other Hypoglycemic Agents) Table 39. Global Polypeptide Drug Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 40. Global Polypeptide Drug Sales Volume by Application (2021-2026) & (Tons) Table 41. Global Polypeptide Drug Sales Volume by Application (2027-2032) & (Tons) Table 42. Global Polypeptide Drug Sales Volume Share by Application (2021-2026) Table 43. Global Polypeptide Drug Sales Volume Share by Application (2027-2032) Table 44. Global Polypeptide Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Polypeptide Drug Sales Value by Application (2021-2026) & (US$ Million) Table 46. Global Polypeptide Drug Sales Value by Application (2027-2032) & (US$ Million) Table 47. Global Polypeptide Drug Sales Value Share by Application (2021-2026) Table 48. Global Polypeptide Drug Sales Value Share by Application (2027-2032) Table 49. Global Polypeptide Drug Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 50. Global Polypeptide Drug Sales by Region (2021-2026) & (Tons) Table 51. Global Polypeptide Drug Sales Market Share by Region (2021-2026) Table 52. Global Polypeptide Drug Sales by Region (2027-2032) & (Tons) Table 53. Global Polypeptide Drug Sales Market Share by Region (2027-2032) Table 54. Global Polypeptide Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Polypeptide Drug Sales Value by Region (2021-2026) & (US$ Million) Table 56. Global Polypeptide Drug Sales Value Share by Region (2021-2026) Table 57. Global Polypeptide Drug Sales Value by Region (2027-2032) & (US$ Million) Table 58. Global Polypeptide Drug Sales Value Share by Region (2027-2032) Table 59. Global Polypeptide Drug Market Average Price (US$/Ton) by Region (2021-2026) Table 60. Global Polypeptide Drug Market Average Price (US$/Ton) by Region (2027-2032) Table 61. Global Polypeptide Drug Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 62. Global Polypeptide Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Polypeptide Drug Sales by Country (2021-2026) & (Tons) Table 64. Global Polypeptide Drug Sales Market Share by Country (2021-2026) Table 65. Global Polypeptide Drug Sales by Country (2027-2032) & (Tons) Table 66. Global Polypeptide Drug Sales Market Share by Country (2027-2032) Table 67. Global Polypeptide Drug Sales Value by Country (2021-2026) & (US$ Million) Table 68. Global Polypeptide Drug Sales Value Market Share by Country (2021-2026) Table 69. Global Polypeptide Drug Sales Value by Country (2027-2032) & (US$ Million) Table 70. Global Polypeptide Drug Sales Value Market Share by Country (2027-2032) Table 71. Takeda Company Information Table 72. Takeda Business Overview Table 73. Takeda Polypeptide Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 74. Takeda Polypeptide Drug Product Portfolio Table 75. Takeda Recent Development Table 76. Sanofi Company Information Table 77. Sanofi Business Overview Table 78. Sanofi Polypeptide Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 79. Sanofi Polypeptide Drug Product Portfolio Table 80. Sanofi Recent Development Table 81. Novartis Company Information Table 82. Novartis Business Overview Table 83. Novartis Polypeptide Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 84. Novartis Polypeptide Drug Product Portfolio Table 85. Novartis Recent Development Table 86. Roche Company Information Table 87. Roche Business Overview Table 88. Roche Polypeptide Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 89. Roche Polypeptide Drug Product Portfolio Table 90. Roche Recent Development Table 91. Lilly Company Information Table 92. Lilly Business Overview Table 93. Lilly Polypeptide Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 94. Lilly Polypeptide Drug Product Portfolio Table 95. Lilly Recent Development Table 96. Ferring Pharmaceuticals Company Information Table 97. Ferring Pharmaceuticals Business Overview Table 98. Ferring Pharmaceuticals Polypeptide Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 99. Ferring Pharmaceuticals Polypeptide Drug Product Portfolio Table 100. Ferring Pharmaceuticals Recent Development Table 101. AstraZeneca Company Information Table 102. AstraZeneca Business Overview Table 103. AstraZeneca Polypeptide Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 104. AstraZeneca Polypeptide Drug Product Portfolio Table 105. AstraZeneca Recent Development Table 106. SciClone Pharmaceuticals Company Information Table 107. SciClone Pharmaceuticals Business Overview Table 108. SciClone Pharmaceuticals Polypeptide Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 109. SciClone Pharmaceuticals Polypeptide Drug Product Portfolio Table 110. SciClone Pharmaceuticals Recent Development Table 111. Merck Serono Company Information Table 112. Merck Serono Business Overview Table 113. Merck Serono Polypeptide Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 114. Merck Serono Polypeptide Drug Product Portfolio Table 115. Merck Serono Recent Development Table 116. Ipsen PHarma Biotech Company Information Table 117. Ipsen PHarma Biotech Business Overview Table 118. Ipsen PHarma Biotech Polypeptide Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 119. Ipsen PHarma Biotech Polypeptide Drug Product Portfolio Table 120. Ipsen PHarma Biotech Recent Development Table 121. Asahi Kasei Company Information Table 122. Asahi Kasei Business Overview Table 123. Asahi Kasei Polypeptide Drug Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 124. Asahi Kasei Polypeptide Drug Product Portfolio Table 125. Asahi Kasei Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Polypeptide Drug Distributors List Table 129. Polypeptide Drug Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Polypeptide Drug Product Image Figure 2. Global Polypeptide Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Polypeptide Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Polypeptide Drug Sales (2021-2032) & (Tons) Figure 5. Global Polypeptide Drug Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Polypeptide Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Injection Image Figure 10. Oral Administration Image Figure 11. Transdermal Administration Image Figure 12. Lung Administration Image Figure 13. Nasal Administration Image Figure 14. Global Polypeptide Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 15. Global Polypeptide Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Polypeptide Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Polypeptide Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Polypeptide Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Polypeptide Drug Sales Value Share by Type (2021-2032) Figure 20. Tumor Drug Image Figure 21. Digestive System Drugs (Gastrointestinal Type) Image Figure 22. Immunity Regulating Medicine (Allergy Infection and Immune) Image Figure 23. Urinary System Drug Image Figure 24. Bone and Connective Tissue Types (Thyroid hormones Drug) Image Figure 25. Gynecologic or Obstetric Drug Image Figure 26. Metabolic Drug (Insulin and Other Hypoglycemic Agents) Image Figure 27. Global Polypeptide Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 28. Global Polypeptide Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 29. Global Polypeptide Drug Sales Volume Share by Application (2021-2032) Figure 30. Global Polypeptide Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Polypeptide Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 32. Global Polypeptide Drug Sales Value Share by Application (2021-2032) Figure 33. Global Polypeptide Drug Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 34. Global Polypeptide Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 35. Global Polypeptide Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 36. Global Polypeptide Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 37. North America Polypeptide Drug Sales Value (2021-2032) & (US$ Million) Figure 38. North America Polypeptide Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Europe Polypeptide Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Europe Polypeptide Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Asia-Pacific Polypeptide Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Asia-Pacific Polypeptide Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. South America Polypeptide Drug Sales Value (2021-2032) & (US$ Million) Figure 44. South America Polypeptide Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 45. Middle East & Africa Polypeptide Drug Sales Value (2021-2032) & (US$ Million) Figure 46. Middle East & Africa Polypeptide Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 47. USA Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. USA Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. USA Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Canada Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Canada Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Canada Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Mexico Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Mexico Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Mexico Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Germany Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Germany Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Germany Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. France Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. France Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. France Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. U.K. Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. U.K. Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. U.K. Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Italy Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Italy Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Italy Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Spain Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Spain Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Spain Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Russia Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Russia Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Russia Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Netherlands Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Netherlands Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Netherlands Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Nordic Countries Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Nordic Countries Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Nordic Countries Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. China Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. China Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. China Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Japan Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Japan Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Japan Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. South Korea Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. South Korea Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. South Korea Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. India Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. India Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. India Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Australia Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Australia Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Australia Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Southeast Asia Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Southeast Asia Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Southeast Asia Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Brazil Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Brazil Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Brazil Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Argentina Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Argentina Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Argentina Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Chile Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Chile Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Chile Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Colombia Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Colombia Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Colombia Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Peru Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Peru Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Peru Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Saudi Arabia Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Saudi Arabia Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Israel Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Israel Arabia Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Israel Arabia Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. UAE Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. UAE Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. UAE Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Turkey Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Turkey Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Turkey Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Iran Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Iran Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Iran Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Egypt Polypeptide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 129. Egypt Polypeptide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 130. Egypt Polypeptide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 131. Polypeptide Drug Value Chain Figure 132. Manufacturing Cost Structure Figure 133. Polypeptide Drug Sales Mode & Process Figure 134. Direct Comparison with Distribution Share Figure 135. Distributors Profiles Figure 136. Years Considered Figure 137. Research Process Figure 138. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral Administration
  • Transdermal Administration
  • Lung Administration
  • Nasal Administration
Applications
  • Tumor Drug
  • Digestive System Drugs (Gastrointestinal Type)
  • Immunity Regulating Medicine (Allergy Infection and Immune)
  • Urinary System Drug
  • Bone and Connective Tissue Types (Thyroid hormones Drug)
  • Gynecologic or Obstetric Drug
  • Metabolic Drug (Insulin and Other Hypoglycemic Agents)
Companies covered
  • Takeda
  • Sanofi
  • Novartis
  • Roche
  • Lilly
  • Ferring Pharmaceuticals
  • AstraZeneca
  • SciClone Pharmaceuticals
  • Merck Serono
  • Ipsen PHarma Biotech
  • Asahi Kasei

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Polypeptide Drug Sales Value (2021-2032)
  4. 1.2.2 Global Polypeptide Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Polypeptide Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Polypeptide Drug Market Dynamics
  1. 2.1 Polypeptide Drug Industry Trends
  2. 2.2 Polypeptide Drug Industry Drivers
  3. 2.3 Polypeptide Drug Industry Opportunities and Challenges
  4. 2.4 Polypeptide Drug Industry Restraints
3 Polypeptide Drug Market by Company
  1. 3.1 Global Polypeptide Drug Company Revenue Ranking in 2025
  2. 3.2 Global Polypeptide Drug Revenue by Company (2021-2026)
  3. 3.3 Global Polypeptide Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Polypeptide Drug Average Price by Company (2021-2026)
  5. 3.5 Global Polypeptide Drug Company Ranking (2024-2026)
  6. 3.6 Global Polypeptide Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Polypeptide Drug Company Product Type and Application
  8. 3.8 Global Polypeptide Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Polypeptide Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Polypeptide Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Polypeptide Drug Market by Type
  1. 4.1 Polypeptide Drug Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 Oral Administration
  4. 4.1.3 Transdermal Administration
  5. 4.1.4 Lung Administration
  6. 4.1.5 Nasal Administration
  7. 4.2 Global Polypeptide Drug Sales Volume by Type
  8. 4.2.1 Global Polypeptide Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Polypeptide Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Polypeptide Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Polypeptide Drug Sales Value by Type
  12. 4.3.1 Global Polypeptide Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Polypeptide Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Polypeptide Drug Sales Value Share by Type (2021-2032)
5 Polypeptide Drug Market by Application
  1. 5.1 Polypeptide Drug Application Introduction
  2. 5.1.1 Tumor Drug
  3. 5.1.2 Digestive System Drugs (Gastrointestinal Type)
  4. 5.1.3 Immunity Regulating Medicine (Allergy Infection and Immune)
  5. 5.1.4 Urinary System Drug
  6. 5.1.5 Bone and Connective Tissue Types (Thyroid hormones Drug)
  7. 5.1.6 Gynecologic or Obstetric Drug
  8. 5.1.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents)
  9. 5.2 Global Polypeptide Drug Sales Volume by Application
  10. 5.2.1 Global Polypeptide Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  11. 5.2.2 Global Polypeptide Drug Sales Volume by Application (2021-2032)
  12. 5.2.3 Global Polypeptide Drug Sales Volume Share by Application (2021-2032)
  13. 5.3 Global Polypeptide Drug Sales Value by Application
  14. 5.3.1 Global Polypeptide Drug Sales Value by Application (2021 VS 2025 VS 2032)
  15. 5.3.2 Global Polypeptide Drug Sales Value by Application (2021-2032)
  16. 5.3.3 Global Polypeptide Drug Sales Value Share by Application (2021-2032)
6 Polypeptide Drug Regional Sales and Value Analysis
  1. 6.1 Global Polypeptide Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Polypeptide Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Polypeptide Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Polypeptide Drug Sales by Region (2027-2032)
  5. 6.3 Global Polypeptide Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Polypeptide Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Polypeptide Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Polypeptide Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Polypeptide Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Polypeptide Drug Sales Value (2021-2032)
  12. 6.6.2 North America Polypeptide Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Polypeptide Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Polypeptide Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Polypeptide Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Polypeptide Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Polypeptide Drug Sales Value (2021-2032)
  21. 6.9.2 South America Polypeptide Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Polypeptide Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Polypeptide Drug Sales Value Share by Country, 2025 VS 2032
7 Polypeptide Drug Country-level Sales and Value Analysis
  1. 7.1 Global Polypeptide Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Polypeptide Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Polypeptide Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Polypeptide Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Polypeptide Drug Sales by Country (2027-2032)
  6. 7.4 Global Polypeptide Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Polypeptide Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Polypeptide Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Polypeptide Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Polypeptide Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Polypeptide Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Polypeptide Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Polypeptide Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Polypeptide Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Polypeptide Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Polypeptide Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Polypeptide Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Polypeptide Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Polypeptide Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Polypeptide Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Polypeptide Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Polypeptide Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Polypeptide Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Polypeptide Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Polypeptide Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Polypeptide Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Polypeptide Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Polypeptide Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Polypeptide Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Polypeptide Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Polypeptide Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Polypeptide Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Polypeptide Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Polypeptide Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Polypeptide Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Polypeptide Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Polypeptide Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Polypeptide Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Polypeptide Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Polypeptide Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Polypeptide Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Polypeptide Drug Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Polypeptide Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Polypeptide Drug Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Polypeptide Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Roche Polypeptide Drug Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Lilly
  26. 8.5.1 Lilly Company Information
  27. 8.5.2 Lilly Business Overview
  28. 8.5.3 Lilly Polypeptide Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Lilly Polypeptide Drug Product Portfolio
  30. 8.5.5 Lilly Recent Developments
  31. 8.6 Ferring Pharmaceuticals
  32. 8.6.1 Ferring Pharmaceuticals Company Information
  33. 8.6.2 Ferring Pharmaceuticals Business Overview
  34. 8.6.3 Ferring Pharmaceuticals Polypeptide Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Ferring Pharmaceuticals Polypeptide Drug Product Portfolio
  36. 8.6.5 Ferring Pharmaceuticals Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Polypeptide Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Polypeptide Drug Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 SciClone Pharmaceuticals
  44. 8.8.1 SciClone Pharmaceuticals Company Information
  45. 8.8.2 SciClone Pharmaceuticals Business Overview
  46. 8.8.3 SciClone Pharmaceuticals Polypeptide Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 SciClone Pharmaceuticals Polypeptide Drug Product Portfolio
  48. 8.8.5 SciClone Pharmaceuticals Recent Developments
  49. 8.9 Merck Serono
  50. 8.9.1 Merck Serono Company Information
  51. 8.9.2 Merck Serono Business Overview
  52. 8.9.3 Merck Serono Polypeptide Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Merck Serono Polypeptide Drug Product Portfolio
  54. 8.9.5 Merck Serono Recent Developments
  55. 8.10 Ipsen PHarma Biotech
  56. 8.10.1 Ipsen PHarma Biotech Company Information
  57. 8.10.2 Ipsen PHarma Biotech Business Overview
  58. 8.10.3 Ipsen PHarma Biotech Polypeptide Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Ipsen PHarma Biotech Polypeptide Drug Product Portfolio
  60. 8.10.5 Ipsen PHarma Biotech Recent Developments
  61. 8.11 Asahi Kasei
  62. 8.11.1 Asahi Kasei Company Information
  63. 8.11.2 Asahi Kasei Business Overview
  64. 8.11.3 Asahi Kasei Polypeptide Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Asahi Kasei Polypeptide Drug Product Portfolio
  66. 8.11.5 Asahi Kasei Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Polypeptide Drug Value Chain Analysis
  2. 9.1.1 Polypeptide Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Polypeptide Drug Sales Mode & Process
  6. 9.2 Polypeptide Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Polypeptide Drug Distributors
  9. 9.2.3 Polypeptide Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst